BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients with HCV GT-1. Neither the mechanism of relapse nor the optimal re-treatment strategy for these patients is defined. OBJECTIVE: To assess the safety and efficacy of sofosbuvir plus ledipasvir in patients with chronic HCV GT-1 that relapsed after sofosbuvir plus ribavirin therapy. DESIGN: Phase 2a, open-label study. (ClinicalTrials.gov: NCT01805882). SETTING: Single U.S site. PATIENTS: 14 patients with HCV GT-1 that relapsed after treatment with sofosbuvir plus ribavirin for 24 weeks were re-treated with sofosbuvir plus ledipasvir for 12 weeks. MEASUREMENTS: HCV RNA concentration and population sequencing to detect NS5B S282T mutations. RESULTS: All 14 patients treated with sofosbuvir plus ledipasvir for 12 weeks achieved a sustained virologic response, including 7 with advanced liver disease (Knodell Histology Activity Index score of 3 or 4) and 1 with a detectable NS5B S282T mutation after sofosbuvir plus ribavirin therapy. Sofosbuvir plus ledipasvir was well-tolerated with few adverse events. Four grade 3 events (elevated serum creatinine in a patient with baseline renal insufficiency, hypercholesterolemia, and hypophosphatemia) occurred. There were no grade 4 events or treatment discontinuations. LIMITATION: Small sample size. CONCLUSION: The fixed-dose combination of sofosbuvir plus ledipasvir was efficacious in a small cohort of patients with HCV GT-1 that relapsed after sofosbuvir plus ribavirin therapy, even in the setting of advanced liver disease. Larger studies are needed to confirm these preliminary efficacy results. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Cancer Institute, and Gilead Sciences.
BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients with HCV GT-1. Neither the mechanism of relapse nor the optimal re-treatment strategy for these patients is defined. OBJECTIVE: To assess the safety and efficacy of sofosbuvir plus ledipasvir in patients with chronic HCV GT-1 that relapsed after sofosbuvir plus ribavirin therapy. DESIGN: Phase 2a, open-label study. (ClinicalTrials.gov: NCT01805882). SETTING: Single U.S site. PATIENTS: 14 patients with HCV GT-1 that relapsed after treatment with sofosbuvir plus ribavirin for 24 weeks were re-treated with sofosbuvir plus ledipasvir for 12 weeks. MEASUREMENTS: HCV RNA concentration and population sequencing to detect NS5B S282T mutations. RESULTS: All 14 patients treated with sofosbuvir plus ledipasvir for 12 weeks achieved a sustained virologic response, including 7 with advanced liver disease (Knodell Histology Activity Index score of 3 or 4) and 1 with a detectable NS5B S282T mutation after sofosbuvir plus ribavirin therapy. Sofosbuvir plus ledipasvir was well-tolerated with few adverse events. Four grade 3 events (elevated serum creatinine in a patient with baseline renal insufficiency, hypercholesterolemia, and hypophosphatemia) occurred. There were no grade 4 events or treatment discontinuations. LIMITATION: Small sample size. CONCLUSION: The fixed-dose combination of sofosbuvir plus ledipasvir was efficacious in a small cohort of patients with HCV GT-1 that relapsed after sofosbuvir plus ribavirin therapy, even in the setting of advanced liver disease. Larger studies are needed to confirm these preliminary efficacy results. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases, National Institutes of Health, National Cancer Institute, and Gilead Sciences.
Authors: Sophie Le Pogam; Wen-Rong Jiang; Vincent Leveque; Sonal Rajyaguru; Han Ma; Hyunsoon Kang; Sharon Jiang; Margaret Singer; Samir Ali; Klaus Klumpp; Dave Smith; Julian Symons; Nick Cammack; Isabel Nájera Journal: Virology Date: 2006-05-19 Impact factor: 3.616
Authors: Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg Journal: Ann Intern Med Date: 2012-02-21 Impact factor: 25.391
Authors: Giovanni Migliaccio; Joanne E Tomassini; Steven S Carroll; Licia Tomei; Sergio Altamura; Balkrishen Bhat; Linda Bartholomew; Michele R Bosserman; Alessandra Ceccacci; Lawrence F Colwell; Riccardo Cortese; Raffaele De Francesco; Anne B Eldrup; Krista L Getty; Xiaoli S Hou; Robert L LaFemina; Steven W Ludmerer; Malcolm MacCoss; Daniel R McMasters; Mark W Stahlhut; David B Olsen; Daria J Hazuda; Osvaldo A Flores Journal: J Biol Chem Date: 2003-09-08 Impact factor: 5.157
Authors: Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Andrew S Bae; Karin S Ku; Michael D Miller; Hongmei Mo; Evguenia S Svarovskaia Journal: J Clin Microbiol Date: 2011-06-29 Impact factor: 5.948
Authors: Edward Tam; Anne F Luetkemeyer; Parvez S Mantry; Sanjaya K Satapathy; Peter Ghali; Minhee Kang; Richard Haubrich; Xianlin Shen; Liyun Ni; Gregory Camus; Amanda Copans; Lorenzo Rossaro; Bill Guyer; Robert S Brown Journal: Liver Int Date: 2017-12-05 Impact factor: 5.828
Authors: Benjamin Emmanuel; Samer S El-Kamary; Laurence S Magder; Kristen A Stafford; Man E Charurat; Cheryl Chairez; Mary McLaughlin; Colleen Hadigan; Ludmila Prokunina-Olsson; Thomas R O'Brien; Henry Masur; Shyam Kottilil Journal: J Infect Dis Date: 2020-01-01 Impact factor: 5.226
Authors: Yevgeniy Gindin; Anuj Gaggar; Anna S Lok; Harry L A Janssen; Carlo Ferrari; G Mani Subramanian; Zhaoshi Jiang; Henry Masur; Benjamin Emmanuel; Bhawna Poonia; Shyam Kottilil Journal: Clin Infect Dis Date: 2021-07-01 Impact factor: 9.079
Authors: Thalia Medeiros; Camila de Morais Salviato; Natalia Fonseca do Rosário; Geórgia do Nascimento Saraiva; Eliane Bordalo Cathalá Esberard; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice da Silva Journal: Int J Clin Pharm Date: 2017-10-27